InvaGen Pharmaceuticals, Inc., with Corporate Head Quarters in Hauppauge, New York is a leading generic pharmaceutical company. InvaGen is engaged in Development, Manufacturing, Marketing and Distributing in generic pharmaceuticals with focus on wide range of therapeutic areas including, cardiovascular, anti-infective, CNS, anti-inflammatory, anti-diabetic and anti-depressants. Dosage forms include both immediate release and modified release and extended release of tablets and capsules.

InvaGen has three facilities with over 125,000 sq.ft. of manufacturing and laboratory area and over 500 employees specialized in different fields. InvaGen’s goal is to come up with innovations in generic medicines to improve quality of life for patients from high quality cost effective medicines.

In February 2016, Cipla Ltd., India’s 3rd largest pharmaceutical company, completed the acquisition of InvaGen pharmaceuticals. This acquisition enabled Cipla Ltd. to further strengthen its commitment to serve patients in the U.S. as a ‘top 15 generics firm’ in terms of prescriptions dispensed.